Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Euan MacIntyre

Showing results (21-30 of 35) with videos related to

Pageof 4
Sort By:
Bioorganic & Medicinal Chemistry Letters|February 3, 2007
Lead optimization of 5,6-diarylpyridines as CB1 receptor inverse agonistsChristina B Madsen-Duggan, John S Debenham, Thomas F Walsh, et al.
Bioorganic & Medicinal Chemistry Letters|September 25, 2007
Benzazepinone Nav1.7 blockers: potential treatments for neuropathic painScott B Hoyt, Clare London, Hyun Ok, et al.
Bioorganic & Medicinal Chemistry Letters|November 3, 2005
Synthesis of functionalized 1,8-naphthyridinones and their evaluation as novel, orally active CB1 receptor inverse agonistsJohn S Debenham, Christina B Madsen-Duggan, Thomas F Walsh, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 28, 2002
Melanin-concentrating hormone 1 receptor-deficient mice are lean, hyperactive, and hyperphagic and have altered metabolismDonald J Marsh, Drew T Weingarth, Dawn E Novi, et al.
Bioorganic & Medicinal Chemistry Letters|July 13, 2010
Discovery of potent, selective, and orally bioavailable 3H-spiro[isobenzofuran-1,4'-piperidine] based melanocortin subtype-4 receptor agonistsLiangqin Guo, Zhixiong Ye, Jian Liu, et al.
European Journal of Pharmacology|November 21, 2007
Characterization of a novel and selective cannabinoid CB1 receptor inverse agonist, Imidazole 24b, in rodentsLauren P Shearman, D Sloan Stribling, Ramon E Camacho, et al.
Bioorganic & Medicinal Chemistry Letters|December 8, 2004
Discovery of (2S)-N-[(1R)-2-[4-cyclohexyl-4-[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-4-methyl-2-piperazinecarboxamide (MB243), a potent and selective melanocortin subtype-4 receptor agonistBrenda L Palucki, Min K Park, Ravi P Nargund, et al.
Journal of Medicinal Chemistry|October 4, 2002
Design and pharmacology of N-[(3R)-1,2,3,4-tetrahydroisoquinolinium- 3-ylcarbonyl]-(1R)-1-(4-chlorobenzyl)- 2-[4-cyclohexyl-4-(1H-1,2,4-triazol- 1-ylmethyl)piperidin-1-yl]-2-oxoethylamine (1), a potent, selective, melanocortin subtype-4 receptor agonistIyassu K Sebhat, William J Martin, Zhixiong Ye, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 2, 2005
The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1)Margarita Garcia-Calvo, JeanMarie Lisnock, Herbert G Bull, et al.
Bioorganic & Medicinal Chemistry Letters|March 29, 2011
Discovery of a piperazine urea based compound as a potent, selective, orally bioavailable melanocortin subtype-4 receptor partial agonistQingmei Hong, Raman K Bakshi, Brenda L Palucki, et al.
Pageof 4

Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
Bioorganic & Medicinal Chemistry Letters|February 3, 2007
Lead optimization of 5,6-diarylpyridines as CB1 receptor inverse agonistsChristina B Madsen-Duggan, John S Debenham, Thomas F Walsh, et al.
Bioorganic & Medicinal Chemistry Letters|September 25, 2007
Benzazepinone Nav1.7 blockers: potential treatments for neuropathic painScott B Hoyt, Clare London, Hyun Ok, et al.
Bioorganic & Medicinal Chemistry Letters|November 3, 2005
Synthesis of functionalized 1,8-naphthyridinones and their evaluation as novel, orally active CB1 receptor inverse agonistsJohn S Debenham, Christina B Madsen-Duggan, Thomas F Walsh, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 28, 2002
Melanin-concentrating hormone 1 receptor-deficient mice are lean, hyperactive, and hyperphagic and have altered metabolismDonald J Marsh, Drew T Weingarth, Dawn E Novi, et al.
Bioorganic & Medicinal Chemistry Letters|July 13, 2010
Discovery of potent, selective, and orally bioavailable 3H-spiro[isobenzofuran-1,4'-piperidine] based melanocortin subtype-4 receptor agonistsLiangqin Guo, Zhixiong Ye, Jian Liu, et al.
European Journal of Pharmacology|November 21, 2007
Characterization of a novel and selective cannabinoid CB1 receptor inverse agonist, Imidazole 24b, in rodentsLauren P Shearman, D Sloan Stribling, Ramon E Camacho, et al.
Bioorganic & Medicinal Chemistry Letters|December 8, 2004
Discovery of (2S)-N-[(1R)-2-[4-cyclohexyl-4-[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-4-methyl-2-piperazinecarboxamide (MB243), a potent and selective melanocortin subtype-4 receptor agonistBrenda L Palucki, Min K Park, Ravi P Nargund, et al.
Journal of Medicinal Chemistry|October 4, 2002
Design and pharmacology of N-[(3R)-1,2,3,4-tetrahydroisoquinolinium- 3-ylcarbonyl]-(1R)-1-(4-chlorobenzyl)- 2-[4-cyclohexyl-4-(1H-1,2,4-triazol- 1-ylmethyl)piperidin-1-yl]-2-oxoethylamine (1), a potent, selective, melanocortin subtype-4 receptor agonistIyassu K Sebhat, William J Martin, Zhixiong Ye, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 2, 2005
The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1)Margarita Garcia-Calvo, JeanMarie Lisnock, Herbert G Bull, et al.
Bioorganic & Medicinal Chemistry Letters|March 29, 2011
Discovery of a piperazine urea based compound as a potent, selective, orally bioavailable melanocortin subtype-4 receptor partial agonistQingmei Hong, Raman K Bakshi, Brenda L Palucki, et al.
Pageof 4